thioridazine Side Effects
Also known as: Mellaril
Analysis of 51 adverse event reports submitted to the FDA from 2004 to 2025.
Total Reports
51
Death-Related
8
15.7% of reports
Hospitalizations
17
33.3% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 8 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| COMPLETED SUICIDE | 3 |
| OVERDOSE | 3 |
| TOXICITY TO VARIOUS AGENTS | 3 |
| ACUTE RESPIRATORY FAILURE | 1 |
| ALCOHOL USE | 1 |
| COGNITIVE DISORDER | 1 |
| DEATH | 1 |
| DRUG ABUSE | 1 |
| EATING DISORDER | 1 |
| INFECTION | 1 |
| INTENTIONAL OVERDOSE | 1 |
| IRRITABILITY | 1 |
| MULTIPLE ORGAN DYSFUNCTION SYNDROME | 1 |
| MUSCLE SPASMS | 1 |
| MUSCULOSKELETAL STIFFNESS | 1 |
| PULMONARY SEPSIS | 1 |
| STRIDOR | 1 |
| URTICARIA | 1 |
| WEIGHT DECREASED | 1 |
Reactions in Hospitalization Reports
Top reactions in 17 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| DRUG INEFFECTIVE | 4 |
| AKATHISIA | 3 |
| COGNITIVE DISORDER | 3 |
| LEUKOPENIA | 3 |
| SUICIDE ATTEMPT | 3 |
| WEIGHT INCREASED | 3 |
| ACUTE HEPATIC FAILURE | 2 |
| ACUTE KIDNEY INJURY | 2 |
| ANTIPSYCHOTIC DRUG LEVEL BELOW THERAPEUTIC | 2 |
| DISINHIBITION | 2 |
| DYSLIPIDAEMIA | 2 |
| EUPHORIC MOOD | 2 |
| HYPERTENSION | 2 |
| INCREASED APPETITE | 2 |
| IRRITABILITY | 2 |
| LEUKAEMIA | 2 |
| OBESITY | 2 |
| OBSESSIVE-COMPULSIVE DISORDER | 2 |
| OFF LABEL USE | 2 |
| PAIN | 2 |
Nearby — Related Medications
What the FAERS Data Reveals About thioridazine Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 51 voluntary reports linked to thioridazine and its brand equivalents (Mellaril), spanning 2004 through 2025. Of those, 8 (15.7%) listed death as an outcome and 17 (33.3%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 58% were female and 42% male; age distribution skews toward 18-44, with 13 reports in that bracket. The single most reported reaction is weight increased with 8 submissions, followed by drug ineffective and dyspnoea.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.